Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 4/20 | 0.42 |
| ▸ | CCR1 | P32246 | 6/20 | 0.38 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22886468 | 0.86 | PYGL (0.44) | PYGLCCR1CAPN1CNR1CNR2 | |
| SCHEMBL20027478 | 0.81 | PYGL (0.42) | PYGLCCR1CAPN1HPGDS | |
| SCHEMBL22886634 | 0.80 | PYGL (0.41) | PYGLCCR1CAPN1CNR1CNR2 | |
| SCHEMBL22886625 | 0.79 | PYGL (0.44) | PYGLCAPN1HPGDS | |
| SCHEMBL22886411 | 0.79 | PYGL (0.42) | PYGLCCR1CAPN1 | |
| SCHEMBL22886549 | 0.77 | PYGL (0.35) | PYGLCCR1CAPN1CNR1CNR2 | |
| SCHEMBL22885966 | 0.76 | CTSV (0.48) | PYGLCCR1CAPN1CNR1CNR2 | |
| SCHEMBL20027619 | 0.75 | PYGL (0.44) | PYGLCCR1CAPN1CNR1CNR2 | |
| SCHEMBL20028606 | 0.74 | PYGL (0.43) | PYGLCCR1CNR1CNR2ROCK2 | |
| SCHEMBL7322290 | 0.73 | CHRNB2 (0.52) | PYGLCAPN1HPGDSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | PYGL 719/4885CCR1 3791/4885CAPN1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.